Equity Overview
Price & Market Data
Price: $0.885
Daily Change: +$0.153 / 17.29%
Daily Range: $0.74 - $0.90
Market Cap: $34,142,764
Daily Volume: 979,025
Performance Metrics
1 Week: 26.79%
1 Month: 25.90%
3 Months: -8.97%
6 Months: -25.85%
1 Year: -54.55%
YTD: -27.69%
Company Details
Employees: 28
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.